Skip to main content

HepaGam B FDA Approval History

FDA Approved: Yes (First approved January 30, 2006)
Brand name: HepaGam B
Generic name: hepatitis B immune globulin
Company: Cangene
Treatment for: Exposure to Hepatitis B Virus

HepaGam B is hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the hepatitis B virus. HepaGam B is indicated for treatment following acute exposure to hepatitis B virus.

Development timeline for HepaGam B

Jan 30, 2006Approval HepaGam B - Cangene - Treatment for Exposure to Hepatitis B

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.